Jacobs Levy Equity Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Jacobs Levy Equity Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-19,300	Closed	-$266K	–	1131
2018 Q2	$266K	Hold	19,300	–	–	﹤0.01%	909
2018 Q1	$175K	Sell	19,300 -87,341	-82%	-$482K	﹤0.01%	943
2017 Q4	$456K	Buy	106,641 +77,600	+267%	+$370K	0.01%	771
2017 Q3	$41K	Sell	29,041 -112,731	-80%	-$157K	﹤0.01%	933
2017 Q2	$213K	Buy	141,772 +113,145	+395%	+$243K	﹤0.01%	826
2017 Q1	$74K	Sell	28,627 -47,747	-63%	-$110K	﹤0.01%	880
2016 Q4	$195K	Buy	76,374 +26,620	+54%	+$76.4K	﹤0.01%	838
2016 Q3	$154K	Sell	49,754 -17,739	-26%	-$55.3K	﹤0.01%	935
2016 Q2	$217K	Buy	+67,493	New	+$247K	﹤0.01%	991
2015 Q1	–	Sell	-36,400	Closed	-$229K	–	927
2014 Q4	$229K	Buy	+36,400	New	+$222K	﹤0.01%	722

Other funds holding ECYT

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Jacobs Levy Equity Management's ECYT Position: Q3 2018 in Review

Jacobs Levy Equity Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q3 2018, closing a stake of 19,300 shares — an estimated $266K sold.

Jacobs Levy Equity Management first reported a position in ECYT in Q4 2014 and held it in 10 quarters. The position peaked at $456K in Q4 2017. 139 funds tracked by Wall St. Rank hold ECYT as of Q3 2018.

Jacobs Levy Equity Management reported no remaining Endocyte, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
Jacobs Levy Equity Management sold 19,300 Endocyte, Inc. Common Stock shares in Q3 2018, an estimated $266K.
Jacobs Levy Equity Management first reported a position in Endocyte, Inc. Common Stock in Q4 2014 and held it in 10 quarters.
Jacobs Levy Equity Management's Endocyte, Inc. Common Stock position peaked at $456K in Q4 2017.
139 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2018.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2018, filed 14 Nov 2018.